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The origin of the fibronectin (FN) found in the extracellular
matrix of tissues has not been defined experimentally. Previous
studies suggest that there is contribution from both local tissue
production and transfer fromplasma, but the extent of this phe-
nomenon has not been addressed. We have shown before that
engineeredmice constitutively expressing extra domain A-con-
taining FN (EDAFN) have a significant decrease of FN levels in
plasma andmost tissues.We showed that hepatocytes modified
to produceEDAFNhavenormal extracellularmatrix-FN levels
but secrete less soluble FN.When we performed a liver-specific
EDA-exon deletion in these animals, FN levels were restored
both in plasma and tissues. Therefore, an important fraction of
tissue FN, approximately an equal amount of that produced by
the tissue itself, is actually plasma-derived, suggesting that
plasma is an important source of tissue FN. The present results
have potential significance for understanding the contributions
of plasma FN, and perhaps other plasma proteins, in the modu-
lation of cellular activities and in the formation of the extracel-
lular matrix of tissues.
Fibronectins (FN)3 are a family of multifunctional glycopro-
teins known to play key roles in fundamental processes related
to adhesive andmigratory behavior of cells, such as embryogen-
esis, malignancy, homeostasis, wound healing, and mainte-
nance of tissue integrity (1). FN generates protein diversity as a
consequence of alternative processing of a single primary tran-
script at three different sites, the extra domain A (EDA), the
extra domain B (EDB), and the type III homologies connecting
segment (IIICS) (2–4). Twomajor forms of FNexist, plasmaFN
(pFN) and cellular FN. pFN is a soluble dimeric form that is
secreted into the bloodstream by hepatocytes (5, 6) and found
at 300 and 580 g/ml in plasma of humans and mice, respec-
tively (1, 7). pFN lacks both the EDA and EDB domains,
whereas cellular FN is locally produced and deposited as insol-
uble fibrils in the extracellular matrix of tissues and contains
these domains at variable proportions (1, 8, 9). Previous studies
suggested that circulating pFN contributes to the extracellular
matrix of tissues (10, 11) but the extent of the phenomenon has
not been addressed.
The levels of FN in plasma are critical for hemostasis, tis-
sue repair, and susceptibility to infections. Depletion of pFN
(liver-specific knockout of FN) results in increased brain
injury after transient focal cerebral ischemia (12), a delay in
thrombus formation and decreased thrombus stability (13),
decreased angiogenesis (14), and increased susceptibility to
bacterial infections (15). Heterozygous null FN mice appear
healthy and fertile (7) but show delayed thrombus growth in
injured arterioles (16). Regrettably, the levels of FN present in
the tissues of heterozygous null FN and in the pFN null mice
have not been reported.
We have previously shown that knock-in mice having con-
stitutive inclusion of the EDA exon of the FN gene (EDA/
strain) had up to 70–80% reduction in the levels of plasma and
tissue FN (17). Taking advantage of the “floxed” EDA exon
present in those mice, we generated liver-specific EDA-null
mice (EDA/CRE) after crossing EDA/ animals with a
transgenic strain expressing theCRE recombinase only in hepa-
tocytes (18). Consequently, hepatocytes of EDA/CRE mice,
without the EDA exon, were able to produce and secrete pFN at
normal levels.
We show here that the levels of pFN were restored in those
mice and also that the levels of tissue FN were similar to those
observed in EDAWT/WT animals. These results showed a major
flow of pFN into the extracellular matrix of tissues and suggest
the importance of the pFN as an essential source of FN for the
tissues. The presented results might have potential significance
for understanding the contributions of pFN, and perhaps other
plasmaproteins, to cellular activities and in the formation of the
extracellular matrix of tissues.
EXPERIMENTAL PROCEDURES
Mice—The generation and genetic background of the mice
devoid of regulated splicing at the EDA exon have been pre-
viously described (17). EDA/ mice were mated with the
transgenic strain Tg Alf pCRE mice, which have CRE recom-
binase under the control of the albumin promoter and
enhancer (18). EDA/WT mice having the CRE recombinase
were mated in order to obtain EDA/ mice with the CRE
transgene (EDA/CRE). This strain expresses the CRE recom-
binase exclusively in hepatocytes (18). The genotype of mice
was determined by PCR from tail biopsies.
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RNA Preparation and Reverse Transcription (RT)-PCR
Analysis—Total RNA was prepared from freshly extracted tis-
sues and cells as described (19). The radioactive RT-PCR reac-
tions were performed and quantified as previously described
(20).
Protein Extracts andWesternBlotAnalysis—Micewere anes-
thetized with 2.5% Avertin (300 l/20 g mouse), and organs
were perfused with 25 ml of cold phosphate-buffered saline
through the left ventricle of the heart.Organswere immediately
dissected and snap-frozen in liquid nitrogen. Organs were
homogenized, andprotein contentwas determinedbyBradford
protein assay (Bio-Rad). Identical amounts of protein sample
were run on a 6% SDS-PAGE and analyzed by Western blot
with polyclonal rabbit anti-FN antibody (50 g of protein
extract, 1:1500; Sigma), anti-EDA 3E2 monoclonal antibody
(100 g of protein extract, 1:300; Sigma), or anti -tubulin
monoclonal antibody (20 g of protein extract, E7, 1:3000;
Developmental Studies Hybridoma Bank, University of Iowa)
as described (17). Three animals per genotype were analyzed.
To determine the efficiency of perfusion and elimination of
plasma proteins in each of the organs analyzed, a Western blot
analysis of 50 g of protein extract was performed using an
anti-mouse IgG antibody (1:2000; DAKO). Serial ECL exposi-
tions of the membranes were performed to determine the opti-
mum linear range to quantify the signals. Films were scanned
with the Versadoc (Bio-Rad) and quantified with the help of the
Quantity One software package (Bio-Rad).
Bile was collected by holding the
gallbladder with forceps. Two l of
each sample were mixed with pro-
tein loading buffer (0.125 Tris-HCl,
pH 6.8, 4% SDS, 20% glycerol, and
0.002% bromphenol blue) and
boiled for 5 min. Bile FN was ana-
lyzed by Western blot as described
above.
In Vivo Labeling of Hepatocytes—
Hepatocytes were purified by the
two-step collagenase perfusionmeth-
od (21), using Liver Digest Medium
(Invitrogen) as described by the
manufacturers. Hepatocytes were
plated in rat tail collagen for 1 h,
washed, and then incubated for
24 h with Met-Cys-free medium
supplemented with 300 Ci/ml of
[35S]Met/Cys (ProMix; Amersham
Biosciences). The supernatant was
collected, and a fraction was affin-
ity-purified with gelatin-Sepha-
rose as described (22, 23).
Southern Blot Analysis of Tis-
sues—DNA was extracted from tis-
sues, and 15 g were digested with
HindIII. The DNA was then run in
an agarose gel and blotted onto
Z-Probe membrane. A probe corre-
sponding to the exon downstream
to the EDA exon was used as described (17).
Immunohistochemistry of Tissue Sections—Organs were
fixed in 4% formaldehyde and paraffin-embedded. 4-m sec-
tions of each tissue were cut and incubated with affinity-puri-
fied polyclonal rabbit anti-FN antibody (1:200; Sigma). Then
sections were incubated with biotinylated goat anti-rabbit IgG
(5g/ml; VectaStain) followedby avidin-biotin-peroxidasemix
(ABC Reagent; Vector Laboratories), 3,3-diaminobenzidine
peroxidase substrate (Vector Laboratories), and Gill’s hema-
toxylin (Vector Laboratories). An AS LMD Leica microscope
was used to visualize and photograph the sections.
RESULTS
Hepatocytes of EDA/ Mice Have Normal Levels of Extra-
cellular Matrix-FN but Do Not Secrete pFN—We have previ-
ously observed that mice having constitutive inclusion of the
EDA exon of the FN gene (Fig. 1A) had a significant decrease of
FN in plasma and inmost tissues (17, 20). Further characteriza-
tion of pFN levels (embryo, young, and adult mice) from
EDA/ mice showed very low amounts compared with
EDAWT/WT and EDA/ mice (Fig. 1, B and C). Embryos had
60% of the pFN levels in the control sample, whereas young and
adult EDA/ mice showed a higher decrease in pFN levels.
The decrease in pFN was due neither to lower levels in mRNA
in tissues of EDA/mice (17) nor to a reduced FN production
by EDA/ tissues, as FN secreted by EDA/ embryonic
fibroblasts or adult heart fibroblasts was similar to that pro-
FIGURE 1. EDA/ embryos have a decrease in the levels of pFN. A, radioactive RT-PCR analysis of the EDA
exon of total RNA extracted from liver, brain, heart, lung, and testis from EDAWT/WT, EDA/, and EDA/mice.
The position of the EDA-containing (EDA) and the EDA-lacking (EDA) bands are indicated. B, Western blot
analysis of pFN from 18.5-pc embryos, 1-, 6-, and 14-day-old babies, 2.5- and 30-month-old adult mice from
EDAWT/WT, EDA/, and EDA/ animals. The samples corresponding to 18.5-pc and 1-day-old time points are
pools of 4–6 animals/genotype. Note that the EDAFN migrates at a different size from the EDA FN by
SDS-PAGE. C, the intensity of the signals in panel Bwas quantified with the help of the Quantity One software.
The signal obtained in the EDAWT/WT samples was considered 100%. Data are presented as themean S.D. of
three independent animals/genotype.
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duced by the EDAWT/WT fibroblasts, excluding a general defect
(17).
The specific degradation of FN in the EDA/mice by pro-
teases was ruled out by a series of experiments: 1) Metallopro-
teinase activity levels in plasma and tissues by gelatin zymogra-
phy analysis were similar among EDAWT/WT, EDA/, and
EDA/ mice (supplemental Fig. S1, A and B); 2) [35S]Met-
labeled fragments of FN containing or not containing the EDA
exon were not differentially degraded when incubated with
EDAWT/WT or EDA/ tissue extracts or plasma in the absence
of protease inhibitors (supplemental Fig. S1, C and D); 3) no
increase in FN degradation rate was observed after mixing pro-
tein extracts fromEDA/ or EDAWT/WT liver with those orig-
inating from different organs or plasma from EDA/mice in
the absence of protease inhibitors (data not shown); 4)Western
blot analysis of tissue extracts done with different sets of
anti-FN polyclonal antibodies, run on 5–17% gradient gel, did
not show any specific degradation products in EDA/ mice
(data not shown).
Because the hepatocytes are the source of pFN (5, 6), we
performed metabolic labeling of hepatocyte primary cultures
from EDAWT/WT, EDA/, and EDA/ livers followed by FN
affinity purification of the conditionedmedium to analyze pFN
production. We observed a decreased secretion of pFN by the
EDA/ hepatocytes, suggesting that the reduced levels in pFN
in the EDA/mice were the consequence of a defect in hepa-
tocytes (Fig. 2,A and B). However, the FN amounts detected by
Western blot in hepatocyte cell extracts were similar (Fig. 2C).
Additionally, the decrease of pFN in EDA/ embryos (Fig. 1B)
but not in embryonic tissues (17) confirmed that the deficiency
in FN secretion was limited only to
EDA/ hepatocytes. These results
showed that EDA/ hepatocytes
were unable to secrete pFN in nor-
mal amounts.We hypothesized that
the reduced levels of tissue FNcould
be due to the decreased supply of FN
from plasma to tissues.
Generation of Liver-specific EDA
Null Mice—To determine the ex-
tent of FN flow into tissues we
restored the capacity of hepato-
cytes to produce pFN not contain-
ing the EDA exon by cross-breed-
ing EDA/mice with a transgenic
strain expressing the CRE recom-
binase only in hepatocytes (18).
The aim was to perform a tissue-
specific deletion of the EDA exon
without modifying the EDA
allele in other cell types and tissues
(Fig. 3, A and B). Southern blot
analysis of different tissues from
the EDA/ mice carrying the
liver-specific CRE recombinase
(EDA/CRE mice) showed CRE-
mediated recombination only in
the liver (Fig. 3C). The percentage
FIGURE 2. Hepatocytes of EDA/ mice do not secrete soluble EDA
fibronectin. A, hepatocytes from EDAWT/WT, EDA/, and EDA/ animals
were isolated, plated, and metabolically labeled with [35S]Met/Cys for 24 h.
Identical aliquots of the conditionedmediumwere run in a 6%SDS-PAGE and
autoradiographed. B, equal quantities of the samples prepared in panel A
were affinity-purified with a gelatin-agarose resin, eluted, separated in an
SDS-PAGE, and autoradiographed. C, total cell extracts prepared from equal
number of hepatocytes from EDAWT/WT, EDA/, and EDA/mice cultured
in non-radioactive medium were collected after 24 h and analyzed by West-
ern blot with a polyclonal anti-FN antibody. D, total cell extracts from the
hepatocytes used inpanel Awere collected, and identical aliquotswere run in
a 6% SDS-PAGE and autoradiographed. Molecular weight markers are
indicated.
FIGURE 3. Liver-specific deletion of the EDA exon. A, scheme of the Alf P-Cre transgene. The CRE recombi-
nase (dotted box) is expressed under the control of the mouse albumin enhancer and promoter (dashed box)
and themouse-fetoprotein enhancer (gray box). Correct polyadenylationwas directed by the hGH fragment
(empty box). B, partialmap of the EDA and EDA FN alleles. The EDA exon is indicated as a dashed box and the
lox-P sites as black triangles. HindIII sites (H), the probe used in panel C (black line below1 exon), the flanking
exons (1 and1), and the expected size of HindIII-digested fragments are as indicated. C, EDA/micewere
crossedwith a transgenic strain expressing the CRE recombinase in hepatocytes. Southern blot analysis of the
different tissues from EDA/CRE mice was performed, and specific recombination was observed only in the
liver. EDA and EDA bands are indicated. Liver DNA samples from three mice are shown. Tissues are as
indicated: K, kidney; H, heart; L, lung; T, testis; M, skeletal muscle; I, intestine; Ta, tail; B, brain; M, molecular
weight markers. D, RT-PCR analysis showing the inclusion/exclusion of the EDA exon in total RNA prepared
from liver and purified hepatocytes from the different genotypes. The position of the EDA and EDAbands is
indicated.
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of recombination in liver was
60–70%. Because hepatocytes
constitute 60% of the total number
of cells present in the liver (24), one
can consider that the percentage of
recombination in hepatocytes was
close to 100%. RT-PCR analysis
confirmed the absence of the EDA
exon in the FN mRNA both in liver
and purified hepatocytes from
EDA/CRE mice (Fig. 3D).
FN Levels Are Restored in
EDA/CRE Mice—Tissues and
plasma from EDA/ mice express-
ing the hepatocyte-specific CRE re-
combinasewere analyzed byWestern
blot with polyclonal anti-FN and
anti-EDA-specificantibodies.Asex-
pected, pFN levels were completely
restored in the EDA/CRE mice
(Fig. 4A). Tissue extracts prepared
from EDA/CRE mice contained
amounts of FN similar to that found
in EDAWT/WT mice (Fig. 4A). The
amount of FN present in the extra-
cellular matrix of tissues from EDA/CRE mice that was
derived from plasma was 60% in testis and 40% in other
tissues such as brain, heart, and lung (Fig. 4B). These results
clearly indicate that an important proportion of the FN present
in the extracellular matrix of adult tissues derives from plasma.
Consequently, the amount of FN that is synthesized and depos-
ited locally in tissues is much lower than believed.
We then used the monoclonal antibody 3E2 to specifically
detect the EDA-containing FN isoform. As expected, no
EDAFN was present in the plasma of EDAWT/WT mice.
Additionally, we did not detect EDAFN in the plasma of
EDA/CRE mice, indicating a high efficiency of CRE-medi-
ated recombination in hepatocytes. The EDAFN isoform in
liver was clearly visible only in the EDA/ samples (Fig. 5A,
lanes 4–9), confirming again the Southern blot and RT-PCR
data (Fig. 3, C andD). The absence of EDAFN in the plasma
of EDA/CRE mice also suggests that the FN flow is mainly
from plasma to tissues and not vice versa (Fig. 5A, lanes 1–3).
No differences were observed in the levels of EDAFN in
testis (Fig. 5, B and C) and in other tissues (data not shown)
between the EDAWT/WT and EDA/CRE samples, suggest-
ing that the observed differences in tissue FN among the
different genotypes corresponded to EDAFN incorporated
from plasma into the extracellular matrix of tissues.
To ensure that the detected levels of FN in tissues were not
due to non-complete perfusion of the organs, we performed
Western blot analysis of the plasma globulins that remained in
each tissue after perfusion and normalized the protein load
with the -tubulin signal. Supplemental Fig. S2 shows that the
remaining globulin levels after tissue perfusion were 10% of
the levels seen in the non-perfused organs. Because most
plasma proteins were washed out from the perfused organs, the
FIGURE 4. Plasma and tissues from EDA/CRE mice have normal FN levels. A, plasma and protein
extracts were prepared from EDAWT/WT, EDA/, and EDA/CRE mice (3 month-old), and total FN levels
were detected by Western blot analysis. The protein load was controlled by detecting -tubulin in the
same extracts. B, the intensity of the signals in panel A was quantified with the help of the Quantity One
software. The ratio between FN and -tubulin signals was used for normalization, and results are shown in
the bar graph. The ratio obtained in the EDAWT/WT samples was considered 100%. Themean S.D. of three
independent experiments is shown.
FIGURE 5. A, plasma from EDA/CRE mice has no EDA-containing FN. Plasma
and liver protein extracts prepared from EDAWT/WT, EDA/, and EDA/CRE
mice were analyzed for the presence of the EDA domain with the 3E2 anti-
EDA monoclonal antibody. B, similar levels of EDAFN were seen in tissues
from all three genotypes. The same protein extracts from testis used in Fig. 4
were analyzed by Western blot with the 3E2 anti-EDA monoclonal antibody.
C, the ratio between EDAFN and -tubulin signals was used for normaliza-
tion, and results are shown in the bar graph. The ratio obtained in the
EDAWT/WT samples was considered 100%. Data are presented as the mean
S.D. of three independent animals/genotype.
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differences of FN levels among the different strains were not
due to residual contamination of pFN.
Immunostaining of Tissue Sections Confirmed the Decrease of
FN Levels in EDA/ Tissues and the Recovery in Tissues of
EDA/CRE Mice—The above results were confirmed by
immunohistochemical analysis of tissue sections. Similar levels
of FN-specific signal were detected in the sinusoids of liver
samples prepared from all three genotypes (Fig. 6, A–C, black
arrows). In the brain sections of EDAWT/WT and EDA/CRE
mice a stronger FN-specific signal, probably associatedwith the
cell surface of glial cells (25–27), was observed when compared
with the EDA/ mice (Fig. 6E, white arrows). Similarly, in
testis tissue sections, a stronger FN-specific signal was observed
in the basement membrane of seminiferous tubules and inter-
stitial regions of EDAWT/WT and EDA/CRE mice compared
with EDA/ samples (Fig. 6H,white arrows). However, we did
not observe intracellular accumulation of FN in the tissue sec-
tions of EDA/ mice by immunohistochemical analysis (Fig.
6,B, E, andH) or in primary culture of hepatocytes either by FN
immunofluorescence (supplemental Fig. 3) or by metabolic
labeling (Fig. 2D).
Gross histology of tissue samples from all three genotypes
was similar, suggesting that the FN synthesized locally is suffi-
cient to maintain the normal tissue architecture. These results
indicate that there was a flow of FN from plasma to the extra-
cellular matrix of tissues and plasma is an important source of
tissue FN.
DISCUSSION
Our data demonstrate an important and novel role for
plasma proteins, in particular that of fibronectin, in the forma-
tion of the extracellular matrix of tissues and, probably, in the
modulation of cellular activities in
tissues. The concept that there is FN
flow from plasma into tissues or
extracellularmatrix of cells has been
known for a long time. Addition or
injection of soluble FN into the cul-
ture medium of cells or into the
plasma of mice, respectively,
resulted in the incorporation of
FN into the extracellular matrix
(10, 11, 28–30). However, the
magnitude of the contribution of
pFN to the extracellular matrix
was not possible to address with
either model. In the present report
we have shown that in some tis-
sues up to 60% of the fibronectin
present in the extracellular matrix
could be plasma-derived.
Sakai et al. (12) have recently
shown that pFN supports neuronal
survival and reduces brain injury
following transient focal cerebral
ischemia, suggesting the incorpora-
tion of pFN into the injured brain.
Our results confirmed and extended
their observations to non-injured tissues as we showed pFN
incorporation intomost normal organs, including brain. In fact,
we are also demonstrating that this is a general mechanism that
occurs inmost normal tissues, andwe suggest that other plasma
proteins could also become incorporated into the extracellular
matrix of tissues, modulating cellular activities.
Because FN is foundboth in blood andbile fluids, secretion of
FN by hepatocytes seems not to be polarized as proposed for
endothelial cells (31). Furthermore, we also observed a decrease
in FN levels in the bile fluid of EDA/mice (data not shown),
suggesting the absence of an EDA-dependent polarization of
FN secretion in hepatocytes, as postulated for airway epithelial
cells (32). The low levels of soluble FN in the plasma of EDA/
mice and intermediate levels in EDA/WT and EDA/ mice
(data not shown) point toward the existence of a mechanism,
analogous to that observed for the secretion of the IIICS vari-
ants (33), that detects the EDA domain during the secretory
pathway of pFN from hepatocytes and prevents the release of
EDAFN into the bloodstream. The “defective” EDA/EDA
pFN dimers might be formed but their transit through the pFN
secretory pathway might be slower compared with EDA/
EDA dimers. However, immunostaining of tissue sections,
immunofluorescence of primary culture of hepatocytes, or
metabolic labeling of hepatocytes did not reveal any intracellu-
lar accumulation of FN in the liver of EDA/mice, suggesting
that the putative “misfolded” dimers are quickly degraded.
We observed that the amount of pFN supplied to the extra-
cellular matrix of tissues varied among the different organs
analyzed, suggesting that there might be equilibrium
between the amount of FN locally produced by the tissues
and the availability of cellular receptors to incorporate FN
from the plasma pool.
FIGURE6. Immunohistochemicalanalysisof liver,brain, andtestis.Tissue sectionsof liver (A–C), brain (D–F),
and testis (G–I) from EDAWT/WT (A,D, andG), EDA/ (B, E, andH), and EDA/CREmice (C, F, and I) were stained
with an affinity-purified polyclonal anti-FN antibody. The black arrows indicate FN in the extracellularmatrix of
EDAWT/WT and EDA/CRE from different tissues and EDA/ liver.White arrows indicate the decrease in levels
of FN from the same areas of brain and testis only in EDA/mice. S, sinusoids, BM, basementmembrane, and
IR, interstitial region, are indicated by black triangles. The black bars correspond to 50 m.
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To conclude, the presented results might have potential sig-
nificance for understanding the contributions of pFN, and per-
haps other plasma proteins, to cellular activities and in the for-
mation of the extracellular matrix of tissues, as we have shown
that a major fraction of tissue FN is plasma-derived. Because
plasma provides approximately an equal amount of FN as the
tissue itself, we suggest that plasma should be considered an
important source of FN for tissues. Furthermore, hepatocytes
have normal levels of FN in the extracellular matrix but do not
secrete soluble EDAFN, suggesting the existence of separate
secretory pathways for soluble and fibrillar FN.
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mice by RT-PCR using the following primers: Forward 5’
CGGGGTACCACCATGGGCACCATCACCCTGTATGCTGTCACT 3’ and Reverse 5’
CGCGGATCCTTATCAGAGTCCTGACACAATCACCGA 3’ which produce a fragment of 803




) were cloned in pBS-
SKII vector. The in vitro translation was done by a single tube protein system (Novagen), based
on a linked reaction in which transcription by a bacteriophage RNA polymerase is directly
followed by translation with rabbit reticulocytes lysate. The translation products were analyzed
by 10% SDS-PAGE followed by ON autoradiography. Fixed amount of the in vitro translated
products were incubated in the absence of protease inhibitors with protein extracts (prepared in
the absence of protease inhibitors) from tissues for 3h and 24h.
Gelatin Zymography: A total of 20 g of tissue protein extract or 0.2 l of plasma were diluted
in 2X sample buffer (1:1) without adding any reducing agent. The samples were run on a 10%
polyacrylamide gel polymerized in the presence of 0.2% gelatin. After electrophoresis, the gel
was washed once for 15 minutes and then overnight in 100 ml wash buffer (2.5% Triton-X100,
50 mM Tris-HCl, pH 7.5 and 5 mM CaCl2) to remove the sodium dodecyl sulfate (SDS). The gel
was rinsed three times in water, followed by a 24 h incubation at 37ºC in incubation buffer (50
mM Tris-HCl, pH 7.5 and 5 mM CaCl2) and was stained for 4 hours in Coomassie Brilliant Blue.
The absence of coloration indicates the digestion of gelatin by metalloproteinases. In a parallel
gel, the same extracts were run and stained with Coomasie Blue.
Immunofluorescence of primary cultures of hepatocytes: Hepatocytes were prepared as
described in the Materials and Methods Section, plated onto rat-tail collagen coated cover slips
and cultured for the indicated times. Cells were fixed and incubated with an affinity purified anti-
FN rabbit antibody, then with a FITC labeled secondary antibody. Nuclei were stained with
Hoetscht. Original magnification was 200x.
Legends to the Supplementary Figures.
Supplementary Figure 1. A and B. MMPs activity was similar in tissues from all genotypes.







amount of plasma was loaded in a gelatin-SDS gel, and the activity of metalloproteinases was
determined. The same samples were loaded in a normal SDS-PAGE and stained with Coomassie
Blue (Panel B) to normalize protein load. C and D. EDA
+
FN was not preferentially degraded.
FN fragments containing or not containing the EDA exon were in vitro translated in the presence
of
35
S-Met/Cys and incubated for different time with tissue extracts in the absence of protein
inhibitors.
Supplementary Figure 2. Perfusion of tissues showed almost no residual plasma proteins.
Equal amounts of proteins samples (50 g) were loaded, run on a 12% SDS-PAGE and analyzed
by Western blot for the presence of plasma gamma globulins. The protein load was controlled by
detecting -tubulin in the same extracts. Lanes 1-7 correspond to serial dilutions of EDA
wt/wt
plasma (each lane is 1:2 of the previous one, starting from 0.05 l to 0.00078 l). Lanes 8, 12 and
15 correspond to non-perfused samples. Lanes 9-11, 13-14 and 16-18 correspond to perfused
samples. The protein load was quantified by the detection of -tubulin in the stripped membrane
(lower panels).
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Supplementary Figure 3. No intracellular FN accumulation is seen in EDA+/+ hepatocytes.




mice and plated onto rat tail collagen
coated glass-slips for 24 or 48 h. Cells were fixed and stained with an affinity purified anti-FN
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